IFNAR1 and COVID-19: Notably, the anti-IFNAR treatment did not affect neutrophil recruitment or NETosis, which is consistent with another COVID-19 model using transgenic human ACE2, where IFNAR knockout inhibited recruitment of monocytes and lymphocytes, but not neutrophils, to infected lungs [48].